Key result
Targeted cancer therapies, including trastuzumab, bevacizumab, imatinib, and sunitinib, are associated with cardiovascular toxicities such as left ventricular dysfunction, heart failure, and hypertension.
Population
Patients receiving targeted cancer therapies
Design
Review
Authors
Loading...
Highlights the need for routine cardiovascular surveillance during targeted oncology regimens; leaves open the optimal cardioprotective strategies.
Targeted cancer therapies such as trastuzumab, bevacizumab, sunitinib, and imatinib are associated with significant cardiovascular toxicities, necessitating awareness of their incidence and molecular mechanisms.
CHEN et al. (2016) conducted a review in Cancer. Targeted cancer therapies (trastuzumab, bevacizumab, imatinib, sunitinib) was evaluated. Targeted cancer therapies, including trastuzumab, bevacizumab, imatinib, and sunitinib, are associated with cardiovascular toxicities such as left ventricular dysfunction, heart failure, and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: